Brookline Capital Acquisition
We intend to focus our search on companies in the life sciences industry. We are led by Dr. Samuel P. Wertheimer, Brookline’s senior scientific advisor and formerly a private equity partner in the private equity group at OrbiMed Advisors.
Our sponsor is an affiliate of Brookline Capital Markets, a division of Arcadia Securities, LLC, which we refer to as “Brookline” in this prospectus, a boutique investment bank with experience providing capital markets and advisory services to public and private life sciences companies, blank check companies (working with management teams during the IPO process, and later in the course of their initial business combinations) and other emerging growth enterprises.
Brookline prides itself on its ability to finance life science companies at all stages from inception to post-IPO. In particular, Brookline has established a strong reputation for financing privately held life science companies. Brookline’s public and private investment teams have completed in excess of 100 transactions, raising more than $4 billion since inception.
|Address||600 Lexington Avenue, 33rd Floor, New York, NY 10022, US|
|Phone Number||(646) 643-6716|
|View Prospectus:||Brookline Capital Acquisition|
|Revenues||$0 mil (last 12 months)|
|Net Income||$0 mil (last 12 months)|
|Price range||$10.00 - $10.00|
|Est. $ Volume||$50.0 mil|
|Manager / Joint Managers||Ladenburg Thalmann|
|Expected To Trade:||1/29/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|